Atle van Beelen Granlund
Background and activities
Our research explores how genes and gene expression in IBD patients differ from healthy controls. We are interested in what gene variants and gene expression within the IBD patient cohort can tell us about each individual's disease prognosis and treatment response.
We perform large genome and gene expression analyses of patient samples and patient-derived cell cultures and correlate these results with clinical observations identifying genes and processes that can be used clinically for improved, more precise treatment and diagnosis. Identified processes and gene variants are followed up to better understand the mechanisms underlying the observed difference. All studies are performed in close collaboration with the other units within CAG-IBD, as well as the clinic.
Objectives for ongoing research activities:
It is our goal that our research should have a direct impact on IBD treatment and prognosis, either through the improvement of clinical practice or by ensuring a greater understanding of IBD pathophysiology.
Scientific, academic and artistic work
Displaying a selection of activities. See all publications in the database
- (2021) Mucosal and faecal neutrophil gelatinase-associated lipocalin as potential biomarkers for collagenous colitis. Journal of gastroenterology. vol. 56.
- (2021) Transcriptomic Profiling of Collagenous Colitis Identifies Hallmarks of Nondestructive Inflammatory Bowel Disease. Cellular and Molecular Gastroenterology and Hepatology (CMGH). vol. 12 (2).
- (2021) Patient derived colonoids as drug testing platforms-Critical importance of oxygen concentration. Frontiers in Pharmacology. vol. 12:679741.
- (2020) Differences in expression of PPARγ in small intestine vs. colon impact the effect of 5-aminosalicylates in inflammatory bowel disease. Journal of Crohn`s and Colitis. vol. 14 (Jan.2020).
- (2020) Whole-genome RNA sequencing in collagenous colitis: a subgroup analysis. Journal of Crohn`s and Colitis. vol. 14 (Jan.2020).
- (2020) The water channel aquaporin 8 is a critical regulator of intestinal fluid homeostasis in collagenous colitis. Journal of Crohn's and Colitis. vol. 14 (7).
- (2020) The serotonin reuptake transporter is reduced in the epithelium of active Crohn's disease and ulcerative colitis. American Journal of Physiology - Gastrointestinal and Liver Physiology. vol. 319 (6).
- (2020) Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn's Disease. Inflammatory Bowel Diseases.
- (2020) Intestinal epithelial cells express immunomodulatory ISG15 during active ulcerative colitis and Crohn's disease. Journal of Crohn's and Colitis. vol. 14 (7).
- (2019) Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Alimentary Pharmacology and Therapeutics. vol. 49 (10).
- (2019) Ulcer-associated cell lineage expresses genes involved in regeneration and is hallmarked by high neutrophil gelatinase-associated lipocalin (NGAL) levels. Journal of Pathology. vol. 248.
- (2018) C-C Motif Ligand 20 (CCL20) and C-C Motif Chemokine Receptor 6 (CCR6) in Human Peripheral Blood Mononuclear Cells: Dysregulated in Ulcerative Colitis and a Potential Role for CCL20 in IL-1β Release. International Journal of Molecular Sciences. vol. 19 (10).
- (2018) Expression of neutrophil gelatinase-associated lipocalin (NGAL) in the gut in Crohn's disease. Cell and Tissue Research. vol. 374 (2).
- (2018) Tu1753 - type 1 Interferon Signaling in Intestinal Epithelial Cells During Active Inflammatory Bowel Disease. Gastroenterology. vol. 154 (6).
- (2017) Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease. Journal of Gastroenterology and Hepatology. vol. 32 (1).
- (2015) The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease. Scandinavian Journal of Gastroenterology. vol. 50 (10).
- (2015) Expression of CCL20 and its corresponding receptor CCR6 is enhanced in active inflammatory bowel disease, and TLR3 mediates CCL20 expression in colonic epithelial cells. PLOS ONE. vol. 10:e0141710 (11).
- (2014) Mucosal toll-like receptor 3-dependent synthesis of complement factor B and systemic complement activation in inflammatory bowel disease. Inflammatory Bowel Diseases. vol. 20 (6).
- (2013) Relevance of TNBS-Colitis in Rats: A Methodological Study with Endoscopic, Historical and Transcripttomic Characterization and Correlation to IBD. PLOS ONE. vol. 8 (1).
- (2013) Whole Genome Gene Expression Meta-Analysis of Inflammatory Bowel Disease Colon Mucosa Demonstrates Lack of Major Differences between Crohn's Disease and Ulcerative Colitis. PLOS ONE. vol. 8 (2).
- (2013) REG gene expression in inflamed and healthy colon mucosa explored by in situ hybridisation. Cell and Tissue Research. vol. 352 (3).
- (2013) Expression of Toll-like receptor-3 is enhanced in active inflammatory bowel disease and mediates the excessive release of lipocalin 2. Clinical and Experimental Immunology. vol. 173 (3).
- (2013) Enhanced expression of CXCL10 in inflammatory bowel disease: Potential role of mucosal toll-like 3 receptor stimulation. Inflammatory Bowel Diseases. vol. 19 (2).
- (2012) The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion. American Journal of Physiology - Gastrointestinal and Liver Physiology. vol. 302 (3).
- (2011) Activation of REG family proteins in colitis. Scandinavian Journal of Gastroenterology. vol. 46 (11).